All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy


Now you can personalise
your MPN Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more

The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
You're logged in! Click here any time to manage your account or log out.
You're logged in! Click here any time to manage your account or log out.

Bookmark this article

During the last steering committee (SC) meeting that was held on April 20, 2022, the SC members discussed about the future of JAK inhibition in myelofibrosis. The session was chaired by John Mascarenhas and involved an analysis from Claire Harrison, Haifa Kathrin Al-Ali, Tiziano Barbui, Jean-Jacques Kiladjian, and Stefan N. Constantinescu.

The future of JAK inhibition in myelofibrosis

Key topics of discussion included: “How to select appropriate JAK inhibitors in patients with myelofibrosis (MF)”; “What patient subsets a JAK inhibitor may capture”; and “The future of JAK inhibitors in treating myelofibrosis, and whether this type of inhibitor will exist as a single agent or in combination therapy at initiation.

More about...


Subscribe to get the best content related to MPN delivered to your inbox